Advertisement
Feature Article

Intensive lipid-modifying therapy: why, when, who and how?

LEON A. SIMONS

Figures

Abstract

Because of issues related to the e cacy, safety and cost e ectiveness of lipid-modifying drugs, physicians have a challenge to ensure these drugs are prescribed for the correct patient at the right time and in the correct manner. Patients have some responsibility to assist in this process, o en in the face of an adverse lay media environment.

Key Points

  • Intensive lipid-modifying therapy is strongly indicated for all instances of secondary cardiovascular disease prevention alongside management of other conventional risk factors.
  • Less intensive lipid-modifying therapy is indicated for primary cardiovascular prevention in selected patients with high cardiovascular risk.
  • Low-density lipoprotein (LDL)-cholesterol targets are necessary and are generally attainable with appropriate therapy.
  • Adverse events sometimes occur in patients receiving intensive lipid-modifying therapy, for a variety of reasons, and require careful and sensitive management.

Figures